Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HBB | P68871 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157513 | 0.80 | RAB9A (0.38) | RAB9AHTTNPC1HPGDMAPT | |
| SCHEMBL7400357 | 0.78 | TSHR (0.38) | RAB9AHTTNPC1MAPTALOX15 | |
| SCHEMBL2470208 | 0.76 | EPHX1 (0.43) | HTTNPC1HPGDMAPTALOX15 | |
| SCHEMBL5190188 | 0.75 | TSHR (0.38) | RAB9AHTTNPC1HPGDMAPT | |
| SCHEMBL5677227 | 0.75 | CES2 (0.41) | HTTNPC1MAPTALOX15HBB | |
| SCHEMBL136598 | 0.74 | MAPT (0.41) | HTTHPGDMAPTALOX15HBB | |
| SCHEMBL305024 | 0.74 | ALDH1A1 (0.37) | HPGDMAPTKMT2AALDH1A1POLB | |
| SCHEMBL7420069 | 0.73 | HTT (0.40) | HTTNPC1MAPTALOX15HBB | |
| SCHEMBL337965 | 0.73 | TSHR (0.38) | HTTNPC1HPGDMAPTALOX15 | |
| SCHEMBL9640021 | 0.73 | CES1 (0.39) | HTTNPC1MAPTALOX15HBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844010-B1 | ISOMERISATION OF PHARMACEUTICAL INTERMEDIATES | LEO PHARMA AS (DK) | 2013-02-13 | — | — | EP | claimed |
| EP-1844010-A1 | ISOMERISATION OF PHARMACEUTICAL INTERMEDIATES | LEO PHARMA A/S (DK) | 2007-10-17 | — | — | EP | claimed |
| US-20070215455-A1 | Isomerisation of pharmaceutical intermediates | LEO PHARMA A/S (DK) | 2007-09-20 | — | — | US | claimed |
| WO-2007082533-A1 | ISOMERISATION OF PHARMACEUTICAL INTERMEDIATES | LEO PHARMA A/S (DK) | 2007-07-26 | — | — | WO | claimed |
| US-12637417-B2 | Method for producing 2-(halogenated methyl)naphthalene and 2-naphthyl acetonitrile | UBE CORPORATION (JP) | 2026-05-26 | — | — | US | disclosed |
| US-20240109840-A1 | METHOD FOR PRODUCING 2-(HALOGENATED METHYL)NAPHTHALENE AND 2-NAPHTHYL ACETONITRILE | API CORPORATION (JP) | 2024-04-04 | — | — | US | disclosed |
| EP-4174049-A1 | METHOD FOR PRODUCING 2-(HALOGENATED METHYL)NAPHTHALENE AND 2-NAPHTHYL ACETONITRILE | API Corporation (JP) | 2023-05-03 | — | — | EP | disclosed |
| EP-1844010-B1 | ISOMERISATION OF PHARMACEUTICAL INTERMEDIATES | LEO PHARMA AS (DK) | 2013-02-13 | — | — | EP | disclosed |
| EP-1844010-A1 | ISOMERISATION OF PHARMACEUTICAL INTERMEDIATES | LEO PHARMA A/S (DK) | 2007-10-17 | — | — | EP | disclosed |
| US-20070215455-A1 | Isomerisation of pharmaceutical intermediates | LEO PHARMA A/S (DK) | 2007-09-20 | — | — | US | disclosed |
| WO-2007082533-A1 | ISOMERISATION OF PHARMACEUTICAL INTERMEDIATES | LEO PHARMA A/S (DK) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637417-B2 | Method for producing 2-(halogenated methyl)naphthalene and 2-naphthyl acetonitrile | CYP1A1, NAT1, CYP1A2 | RAB9A 3738/4885HTT 1315/4885NPC1 77/4885 |
| US-20240109840-A1 | METHOD FOR PRODUCING 2-(HALOGENATED METHYL)NAPHTHALENE AND 2-NAPHTHYL ACETONITRILE | CYP1A1, CYP2E1, NPM1 | RAB9A 3626/4885HTT 672/4885NPC1 482/4885 |
| US-20070215455-A1 | Isomerisation of pharmaceutical intermediates | CYP24A1, CYP2R1, VDR | RAB9A 4458/4885HTT 4626/4885NPC1 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.